Mike Andriole

Mr. Andriole is the Chief Business Officer and CFO at Chimerix. He has nearly 20 years of experience in a range of financial, strategic and corporate development roles within the biotechnology industry where he has led over $10 billion of corporate and financial transactions. Most recently, Mr. Andriole served as CFO of Endocyte, Inc., a leader in developing targeted treatments for prostate and other cancers where he was instrumental in managing the company through a series of strategic transactions culminating in a sale to Novartis for $2.1 billion, including two 2018 financings from US and European investors raising nearly $300 million in capital. Within oncology, Mr. Andriole’s experience includes the development or acquisition of a diverse set of assets spanning several modalities and many tumor types, resulting in the licensing/acquisition of assets which eventually garnered six NCE/BLA approvals with several other molecules still in clinical development.

Prior to Endocyte, Mr. Andriole spent 16 years at Eli Lilly and Company in a range of financial, marketing (neuroscience) and global business development roles. Mr. Andriole earned a BSBA from Xavier University’s Williams School of Business (finance) and an MBA from Indiana University’s Kelley School of Business (finance).